Pharmacovigilance and medication safety monitoring of newer treatments, like bedaquiline, are critical for enhancing treatment support and adherence, especially among drug-resistant tuberculosis patients.
Keyphrases
- drug resistant
- multidrug resistant
- acinetobacter baumannii
- end stage renal disease
- adverse drug
- newly diagnosed
- ejection fraction
- chronic kidney disease
- healthcare
- mycobacterium tuberculosis
- type diabetes
- prognostic factors
- emergency department
- metabolic syndrome
- hiv aids
- pulmonary tuberculosis
- insulin resistance
- hepatitis c virus
- combination therapy
- patient reported
- hiv infected